Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

A cystic fibrosis child with lung function decline.

Fiscarelli EV, Ricciotti G, Rossitto M, Pompilio A, Tuccio Guarna Assanti V, Lucidi V.

J Cyst Fibros. 2019 Jul 9. pii: S1569-1993(19)30819-7. doi: 10.1016/j.jcf.2019.06.015. [Epub ahead of print]

PMID:
31300282
2.

Genetic Polymorphisms Affecting IDO1 or IDO2 Activity Differently Associate With Aspergillosis in Humans.

Napolioni V, Pariano M, Borghi M, Oikonomou V, Galosi C, De Luca A, Stincardini C, Vacca C, Renga G, Lucidi V, Colombo C, Fiscarelli E, Lass-Flörl C, Carotti A, D'Amico L, Majo F, Russo MC, Ellemunter H, Spolzino A, Mosci P, Brancorsini S, Aversa F, Velardi A, Romani L, Costantini C.

Front Immunol. 2019 May 7;10:890. doi: 10.3389/fimmu.2019.00890. eCollection 2019.

3.

Activity and Impact on Resistance Development of Two Antivirulence Fluoropyrimidine Drugs in Pseudomonas aeruginosa.

Imperi F, Fiscarelli EV, Visaggio D, Leoni L, Visca P.

Front Cell Infect Microbiol. 2019 Mar 11;9:49. doi: 10.3389/fcimb.2019.00049. eCollection 2019.

4.

Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: A randomized multicenter study.

Dolce D, Neri S, Grisotto L, Campana S, Ravenni N, Miselli F, Camera E, Zavataro L, Braggion C, Fiscarelli EV, Lucidi V, Cariani L, Girelli D, Faelli N, Colombo C, Lucanto C, Lombardo M, Magazzù G, Tosco A, Raia V, Manara S, Pasolli E, Armanini F, Segata N, Biggeri A, Taccetti G.

PLoS One. 2019 Mar 22;14(3):e0213497. doi: 10.1371/journal.pone.0213497. eCollection 2019.

5.

Evaluation of in vitro activity of ceftolozane-tazobactam compared to other antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Gherardi G, Linardos G, Pompilio A, Fiscarelli E, Di Bonaventura G.

Diagn Microbiol Infect Dis. 2019 Jul;94(3):297-303. doi: 10.1016/j.diagmicrobio.2019.01.012. Epub 2019 Jan 27.

PMID:
30803726
6.

Gut microbiota signatures in cystic fibrosis: Loss of host CFTR function drives the microbiota enterophenotype.

Vernocchi P, Del Chierico F, Russo A, Majo F, Rossitto M, Valerio M, Casadei L, La Storia A, De Filippis F, Rizzo C, Manetti C, Paci P, Ercolini D, Marini F, Fiscarelli EV, Dallapiccola B, Lucidi V, Miccheli A, Putignani L.

PLoS One. 2018 Dec 6;13(12):e0208171. doi: 10.1371/journal.pone.0208171. eCollection 2018.

7.

Prevalence, geographic risk factor, and development of a standardized protocol for fungal isolation in cystic fibrosis: Results from the international prospective study "MFIP".

Delhaes L, Touati K, Faure-Cognet O, Cornet M, Botterel F, Dannaoui E, Morio F, Le Pape P, Grenouillet F, Favennec L, Le Gal S, Nevez G, Duhamel A, Borman A, Saegeman V, Lagrou K, Gomez E, Carro ML, Canton R, Campana S, Buzina W, Chen S, Meyer W, Roilides E, Simitsopoulou M, Manso E, Cariani L, Biffi A, Fiscarelli E, Ricciotti G, Pihet M, Bouchara JP.

J Cyst Fibros. 2019 Mar;18(2):212-220. doi: 10.1016/j.jcf.2018.10.001. Epub 2018 Oct 20. No abstract available.

PMID:
30348610
8.

Identification of FDA-Approved Drugs as Antivirulence Agents Targeting the pqs Quorum-Sensing System of Pseudomonas aeruginosa.

D'Angelo F, Baldelli V, Halliday N, Pantalone P, Polticelli F, Fiscarelli E, Williams P, Visca P, Leoni L, Rampioni G.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01296-18. doi: 10.1128/AAC.01296-18. Print 2018 Nov.

9.

Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against Pseudomonas aeruginosa in Cystic Fibrosis. An Argumentative Review.

Rossitto M, Fiscarelli EV, Rosati P.

Front Microbiol. 2018 May 4;9:775. doi: 10.3389/fmicb.2018.00775. eCollection 2018. Review.

10.

Design of a Broad-Range Bacteriophage Cocktail That Reduces Pseudomonas aeruginosa Biofilms and Treats Acute Infections in Two Animal Models.

Forti F, Roach DR, Cafora M, Pasini ME, Horner DS, Fiscarelli EV, Rossitto M, Cariani L, Briani F, Debarbieux L, Ghisotti D.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02573-17. doi: 10.1128/AAC.02573-17. Print 2018 Jun.

11.

Organization of Patient Management and Fungal Epidemiology in Cystic Fibrosis.

Schwarz C, Bouchara JP, Buzina W, Chrenkova V, Dmeńska H, de la Pedrosa EGG, Cantón R, Fiscarelli E, Le Govic Y, Kondori N, Matos T, Romanowska E, Ziesing S, Sedlacek L.

Mycopathologia. 2018 Feb;183(1):7-19. doi: 10.1007/s11046-017-0205-x. Epub 2017 Nov 3.

PMID:
29098487
12.

Evolution of Stenotrophomonas maltophilia in Cystic Fibrosis Lung over Chronic Infection: A Genomic and Phenotypic Population Study.

Esposito A, Pompilio A, Bettua C, Crocetta V, Giacobazzi E, Fiscarelli E, Jousson O, Di Bonaventura G.

Front Microbiol. 2017 Aug 28;8:1590. doi: 10.3389/fmicb.2017.01590. eCollection 2017.

13.

A Different Microbiome Gene Repertoire in the Airways of Cystic Fibrosis Patients with Severe Lung Disease.

Bacci G, Mengoni A, Fiscarelli E, Segata N, Taccetti G, Dolce D, Paganin P, Morelli P, Tuccio V, De Alessandri A, Lucidi V, Bevivino A.

Int J Mol Sci. 2017 Jul 29;18(8). pii: E1654. doi: 10.3390/ijms18081654.

14.

A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis.

Moretti S, Renga G, Oikonomou V, Galosi C, Pariano M, Iannitti RG, Borghi M, Puccetti M, De Zuani M, Pucillo CE, Paolicelli G, Zelante T, Renauld JC, Bereshchenko O, Sportoletti P, Lucidi V, Russo MC, Colombo C, Fiscarelli E, Lass-Flörl C, Majo F, Ricciotti G, Ellemunter H, Ratclif L, Talesa VN, Napolioni V, Romani L.

Nat Commun. 2017 Jan 16;8:14017. doi: 10.1038/ncomms14017.

15.

Stenotrophomonas maltophilia Phenotypic and Genotypic Diversity during a 10-year Colonization in the Lungs of a Cystic Fibrosis Patient.

Pompilio A, Crocetta V, Ghosh D, Chakrabarti M, Gherardi G, Vitali LA, Fiscarelli E, Di Bonaventura G.

Front Microbiol. 2016 Sep 30;7:1551. eCollection 2016.

16.

Major discrepancies between what clinical trial registries record and paediatric randomised controlled trials publish.

Rosati P, Porzsolt F, Ricciotti G, Testa G, Inglese R, Giustini F, Fiscarelli E, Zazza M, Carlino C, Balassone V, Fiorito R, D'Amico R.

Trials. 2016 Sep 23;17(1):430.

17.

Correction: Pyrosequencing Unveils Cystic Fibrosis Lung Microbiome Differences Associated with a Severe Lung Function Decline.

Bacci G, Paganin P, Lopez L, Vanni C, Dalmastri C, Cantale C, Daddiego L, Perrotta G, Dolce D, Morelli P, Tuccio V, De Alessandri A, Fiscarelli EV, Taccetti G, Lucidi V, Bevivino A, Mengoni A.

PLoS One. 2016 Aug 1;11(8):e0160726. doi: 10.1371/journal.pone.0160726. eCollection 2016.

18.

Pyrosequencing Unveils Cystic Fibrosis Lung Microbiome Differences Associated with a Severe Lung Function Decline.

Bacci G, Paganin P, Lopez L, Vanni C, Dalmastri C, Cantale C, Daddiego L, Perrotta G, Dolce D, Morelli P, Tuccio V, De Alessandri A, Fiscarelli EV, Taccetti G, Lucidi V, Bevivino A, Mengoni A.

PLoS One. 2016 Jun 29;11(6):e0156807. doi: 10.1371/journal.pone.0156807. eCollection 2016. Erratum in: PLoS One. 2016;11(8):e0160726.

19.

IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis.

Iannitti RG, Napolioni V, Oikonomou V, De Luca A, Galosi C, Pariano M, Massi-Benedetti C, Borghi M, Puccetti M, Lucidi V, Colombo C, Fiscarelli E, Lass-Flörl C, Majo F, Cariani L, Russo M, Porcaro L, Ricciotti G, Ellemunter H, Ratclif L, De Benedictis FM, Talesa VN, Dinarello CA, van de Veerdonk FL, Romani L.

Nat Commun. 2016 Mar 14;7:10791. doi: 10.1038/ncomms10791.

20.

Cooperative pathogenicity in cystic fibrosis: Stenotrophomonas maltophilia modulates Pseudomonas aeruginosa virulence in mixed biofilm.

Pompilio A, Crocetta V, De Nicola S, Verginelli F, Fiscarelli E, Di Bonaventura G.

Front Microbiol. 2015 Sep 16;6:951. doi: 10.3389/fmicb.2015.00951. eCollection 2015.

21.

Determination of ciprofloxacin and levofloxacin in human sputum collected from cystic fibrosis patients using microextraction by packed sorbent-high performance liquid chromatography photodiode array detector.

Locatelli M, Ciavarella MT, Paolino D, Celia C, Fiscarelli E, Ricciotti G, Pompilio A, Di Bonaventura G, Grande R, Zengin G, Di Marzio L.

J Chromatogr A. 2015 Nov 6;1419:58-66. doi: 10.1016/j.chroma.2015.09.075. Epub 2015 Sep 26.

PMID:
26431855
22.

In vitro activity of colistin against biofilm by Pseudomonas aeruginosa is significantly improved under "cystic fibrosis-like" physicochemical conditions.

Pompilio A, Crocetta V, Pomponio S, Fiscarelli E, Di Bonaventura G.

Diagn Microbiol Infect Dis. 2015 Aug;82(4):318-25. doi: 10.1016/j.diagmicrobio.2015.01.006. Epub 2015 Jan 23.

PMID:
26004353
23.

Changes in cystic fibrosis airway microbial community associated with a severe decline in lung function.

Paganin P, Fiscarelli EV, Tuccio V, Chiancianesi M, Bacci G, Morelli P, Dolce D, Dalmastri C, De Alessandri A, Lucidi V, Taccetti G, Mengoni A, Bevivino A.

PLoS One. 2015 Apr 21;10(4):e0124348. doi: 10.1371/journal.pone.0124348. eCollection 2015.

24.

Exposure to extremely low-frequency magnetic field affects biofilm formation by cystic fibrosis pathogens.

Di Bonaventura G, Pompilio A, Crocetta V, De Nicola S, Barbaro F, Giuliani L, D'Emilia E, Fiscarelli E, Bellomo RG, Saggini R.

Future Microbiol. 2014;9(12):1303-17. doi: 10.2217/fmb.14.96.

PMID:
25517897
25.

Characterization of Streptococcus pneumoniae clones from paediatric patients with cystic fibrosis.

Pimentel de Araujo F, D'Ambrosio F, Camilli R, Fiscarelli E, Di Bonaventura G, Baldassarri L, Visca P, Pantosti A, Gherardi G.

J Med Microbiol. 2014 Dec;63(Pt 12):1704-15. doi: 10.1099/jmm.0.072199-0. Epub 2014 Oct 9.

PMID:
25301526
26.

Proteomics boosts translational and clinical microbiology.

Del Chierico F, Petrucca A, Vernocchi P, Bracaglia G, Fiscarelli E, Bernaschi P, Muraca M, Urbani A, Putignani L.

J Proteomics. 2014 Jan 31;97:69-87. doi: 10.1016/j.jprot.2013.10.013. Epub 2013 Oct 19. Review.

27.

Hypoxia promotes danger-mediated inflammation via receptor for advanced glycation end products in cystic fibrosis.

Iannitti RG, Casagrande A, De Luca A, Cunha C, Sorci G, Riuzzi F, Borghi M, Galosi C, Massi-Benedetti C, Oury TD, Cariani L, Russo M, Porcaro L, Colombo C, Majo F, Lucidi V, Fiscarelli E, Ricciotti G, Lass-Flörl C, Ratclif L, Esposito A, De Benedictis FM, Donato R, Carvalho A, Romani L.

Am J Respir Crit Care Med. 2013 Dec 1;188(11):1338-50. doi: 10.1164/rccm.201305-0986OC.

PMID:
24127697
28.

Evaluation of specific immune response in early P. aeruginosa infection in cystic fibrosis patients.

Dolce D, Cariani L, Campana S, Ravenni N, Mergni G, Biffi A, Colombo C, Gagliardini R, Cirilli N, Manso E, Padoan R, Soncini E, Forte FR, D'Aprile A, Ratclif L, Amboni M, Casciaro R, Minicucci L, Borio T, Cosimi A, Vieni G, Zinnarello C, Fiscarelli E, Collura M, Pensabene T, Braggion C, Döring G, Taccetti G.

J Cyst Fibros. 2014 Jan;13(1):116-7. doi: 10.1016/j.jcf.2013.08.003. Epub 2013 Sep 7. No abstract available.

29.

Procalcitonin in detecting neonatal nosocomial sepsis.

Auriti C, Fiscarelli E, Ronchetti MP, Argentieri M, Marrocco G, Quondamcarlo A, Seganti G, Bagnoli F, Buonocore G, Serra G, Bacolla G, Mastropasqua S, Mari A, Corchia C, Prencipe G, Piersigilli F, Ravà L, Di Ciommo V.

Arch Dis Child Fetal Neonatal Ed. 2012 Sep;97(5):F368-70. doi: 10.1136/fetalneonatal-2010-194100. Erratum in: Arch Dis Child Fetal Neonatal Ed. 2012 Nov;97(6):F488.

PMID:
22933097
30.

Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia.

Pompilio A, Crocetta V, Scocchi M, Pomponio S, Di Vincenzo V, Mardirossian M, Gherardi G, Fiscarelli E, Dicuonzo G, Gennaro R, Di Bonaventura G.

BMC Microbiol. 2012 Jul 23;12:145. doi: 10.1186/1471-2180-12-145.

31.

MALDI-TOF MS proteomic phenotyping of filamentous and other fungi from clinical origin.

Del Chierico F, Masotti A, Onori M, Fiscarelli E, Mancinelli L, Ricciotti G, Alghisi F, Dimiziani L, Manetti C, Urbani A, Muraca M, Putignani L.

J Proteomics. 2012 Jun 18;75(11):3314-30. doi: 10.1016/j.jprot.2012.03.048. Epub 2012 Apr 4.

PMID:
22504628
32.

Haemophilus influenzae in children with cystic fibrosis: antimicrobial susceptibility, molecular epidemiology, distribution of adhesins and biofilm formation.

Cardines R, Giufrè M, Pompilio A, Fiscarelli E, Ricciotti G, Di Bonaventura G, Cerquetti M.

Int J Med Microbiol. 2012 Jan;302(1):45-52. doi: 10.1016/j.ijmm.2011.08.003. Epub 2011 Oct 15.

PMID:
22001303
33.

Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients.

Pompilio A, Scocchi M, Pomponio S, Guida F, Di Primio A, Fiscarelli E, Gennaro R, Di Bonaventura G.

Peptides. 2011 Sep;32(9):1807-14. doi: 10.1016/j.peptides.2011.08.002. Epub 2011 Aug 7.

PMID:
21849157
34.

Molecular epidemiology of meticillin-resistant Staphylococcus aureus in Italian cystic fibrosis patients: a national overview.

Cocchi P, Cariani L, Favari F, Lambiase A, Fiscarelli E, Gioffré FV, d'Aprile A, Manso E, Taccetti G, Braggion C, Döring G, de Martino M, Campana S.

J Cyst Fibros. 2011 Dec;10(6):407-11. doi: 10.1016/j.jcf.2011.06.005. Epub 2011 Jul 12.

35.

Phenotypic and genotypic characterization of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis: genome diversity, biofilm formation, and virulence.

Pompilio A, Pomponio S, Crocetta V, Gherardi G, Verginelli F, Fiscarelli E, Dicuonzo G, Savini V, D'Antonio D, Di Bonaventura G.

BMC Microbiol. 2011 Jul 5;11:159. doi: 10.1186/1471-2180-11-159.

36.

Pseudomonas aeruginosa infection in cystic fibrosis caused by an epidemic metallo-β-lactamase-producing clone with a heterogeneous carbapenem resistance phenotype.

Pollini S, Fiscarelli E, Mugnaioli C, Di Pilato V, Ricciotti G, Neri AS, Rossolini GM.

Clin Microbiol Infect. 2011 Aug;17(8):1272-5. doi: 10.1111/j.1469-0691.2011.03466.x. Epub 2011 Mar 7.

37.

Analysis of heat-induced changes in protein expression of Stenotrophomonas maltophilia K279a reveals a role for GroEL in the host-temperature adaptation.

De Carolis E, Posteraro B, Florio AR, Colonna B, Prosseda G, Bugli F, Lorenzetti SR, Fiscarelli E, Inzitari R, Iavarone F, Castagnola M, Fadda G, Sanguinetti M.

Int J Med Microbiol. 2011 Apr;301(4):273-81. doi: 10.1016/j.ijmm.2010.10.001. Epub 2010 Nov 26.

PMID:
21112247
38.

Stenotrophomonas maltophilia strains from cystic fibrosis patients: genomic variability and molecular characterization of some virulence determinants.

Nicoletti M, Iacobino A, Prosseda G, Fiscarelli E, Zarrilli R, De Carolis E, Petrucca A, Nencioni L, Colonna B, Casalino M.

Int J Med Microbiol. 2011 Jan;301(1):34-43. doi: 10.1016/j.ijmm.2010.07.003. Epub 2010 Oct 16.

PMID:
20952251
39.

Quantitative recovery of proviral HIV-1 DNA from leukocytes by the Dried Buffy Coat Spot method for real-time PCR determination.

Rossi de Gasperis M, Caione MD, Concato C, Fiscarelli E, Di Pietro N, Salotti V, Putignani L, Menichella D, Callea F.

J Virol Methods. 2010 Dec;170(1-2):121-7. doi: 10.1016/j.jviromet.2010.09.012. Epub 2010 Sep 21.

PMID:
20863854
40.

Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients.

Pompilio A, Crocetta V, Confalone P, Nicoletti M, Petrucca A, Guarnieri S, Fiscarelli E, Savini V, Piccolomini R, Di Bonaventura G.

BMC Microbiol. 2010 Apr 7;10:102. doi: 10.1186/1471-2180-10-102.

41.

Role of excessive inflammatory response to Stenotrophomonas maltophilia lung infection in DBA/2 mice and implications for cystic fibrosis.

Di Bonaventura G, Pompilio A, Zappacosta R, Petrucci F, Fiscarelli E, Rossi C, Piccolomini R.

Infect Immun. 2010 Jun;78(6):2466-76. doi: 10.1128/IAI.01391-09. Epub 2010 Mar 22.

42.

DNA damage and related modifier genes in Italian cystic fibrosis patients.

Sterpone S, Cornetta T, Angioni A, Fiscarelli E, Lucidi V, Testa A, Cozzi R.

Biol Res. 2009;42(4):477-86. doi: /S0716-97602009000400009. Epub 2010 Jan 29.

43.

Subinhibitory concentrations of moxifloxacin decrease adhesion and biofilm formation of Stenotrophomonas maltophilia from cystic fibrosis.

Pompilio A, Catavitello C, Picciani C, Confalone P, Piccolomini R, Savini V, Fiscarelli E, D'Antonio D, Di Bonaventura G.

J Med Microbiol. 2010 Jan;59(Pt 1):76-81. doi: 10.1099/jmm.0.011981-0.

PMID:
19762476
44.

Molecular characterization of virulence determinants of Stenotrophomonas maltophilia strains isolated from patients affected by cystic fibrosis.

Di Bonaventura G, Prosseda G, Del Chierico F, Cannavacciuolo S, Cipriani P, Petrucca A, Superti F, Ammendolia MG, Concato C, Fiscarelli E, Casalino M, Piccolomini R, Nicoletti M, Colonna B.

Int J Immunopathol Pharmacol. 2007 Jul-Sep;20(3):529-37.

PMID:
17880766
45.

Bacillus thuringiensis pulmonary infection: critical role for bacterial membrane-damaging toxins and host neutrophils.

Ghelardi E, Celandroni F, Salvetti S, Fiscarelli E, Senesi S.

Microbes Infect. 2007 Apr;9(5):591-8. Epub 2007 Feb 16.

PMID:
17387030
46.

Transmission of Burkholderia cepacia complex: evidence for new epidemic clones infecting cystic fibrosis patients in Italy.

Campana S, Taccetti G, Ravenni N, Favari F, Cariani L, Sciacca A, Savoia D, Collura A, Fiscarelli E, De Intinis G, Busetti M, Cipolloni A, d'Aprile A, Provenzano E, Collebrusco I, Frontini P, Stassi G, Trancassini M, Tovagliari D, Lavitola A, Doherty CJ, Coenye T, Govan JR, Vandamme P.

J Clin Microbiol. 2005 Oct;43(10):5136-42.

47.

Role of laboratories in population-based surveillance of invasive diseases in Lazio, Italy, 1998-2000.

Faustini A, Fabrizi E, Sangalli M, Bordi E, Cipriani P, Fiscarelli E, Perucci CA.

Eur J Clin Microbiol Infect Dis. 2002 Nov;21(11):824-6. Epub 2002 Nov 9. No abstract available.

PMID:
12461595
48.

Erythromycin-resistant pharyngeal isolates of Streptococcus pyogenes recovered in Italy.

Dicuonzo G, Fiscarelli E, Gherardi G, Lorino G, Battistoni F, Landi S, De Cesaris M, Petitti T, Beall B.

Antimicrob Agents Chemother. 2002 Dec;46(12):3987-90.

49.

Group A streptococcal genotypes from pediatric throat isolates in Rome, Italy.

Dicuonzo G, Gherardi G, Lorino G, Angeletti S, De Cesaris M, Fiscarelli E, Bessen DE, Beall B.

J Clin Microbiol. 2001 May;39(5):1687-90.

50.

Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis.

Sanguinetti M, Ardito F, Fiscarelli E, La Sorda M, D'Argenio P, Ricciotti G, Fadda G.

J Clin Microbiol. 2001 Feb;39(2):816-9.

Supplemental Content

Loading ...
Support Center